3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Conditions
Neoplasms
2
Melanoma
2
Carcinoma, Hepatocellular
2
Uveal Melanoma
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Liver Neoplasms
1
Glioma
1
Glioblastoma
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Advanced Solid Tumors
1
Advanced Cancer
1
Interventions
pembrolizumab
26
Nivolumab
18
enfortumab vedotin
7
avelumab
6
atezolizumab
6
Ipilimumab
6
Magnetic Resonance Spectroscopy
5
fludarabine
4
cabozantinib
4
Gemcitabine
4
Cyclophosphamide
4
Carboplatin
4
Specimen Handling
3
Interleukin-2
3
Docetaxel
3
130-nm albumin-bound paclitaxel
3
aldesleukin
2
Platinum
2
Pemetrexed
2
Paclitaxel
2
Oxaliplatin
2
Immunoglobulin G
2
Fluorodeoxyglucose F18
2
FAPI-46
2
Disulfides
2
Cisplatin
2
Albumin-Bound Paclitaxel
2
vinflunine
1
veliparib
1
valrubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Carcinoma, Transitional Cell
×
relatlimab
×
Clear all
NCT05176483
2026-05-27
STELLAR-002
Exelixis
Phase 1
Recruiting
1,314 enrolled